[Cytoreduction nephrectomy: No future?]

Loic Balssa; François Kleinclauss; Hamadi Almotlak; Antoine Thiery-Vuillemin

doi:10.1016/j.bulcan.2018.08.009

[Cytoreduction nephrectomy: No future?]

Bull Cancer. 2018 Nov;105(11):981-984. doi: 10.1016/j.bulcan.2018.08.009. Epub 2018 Oct 15.

[Article in French]

Authors

Loic Balssa¹, François Kleinclauss², Hamadi Almotlak³, Antoine Thiery-Vuillemin⁴

Affiliations

¹ CHU de Besançon, urologie, boulevard Fleming, 25030 Besançon cedex, France.
² CHU de Besançon, urologie, boulevard Fleming, 25030 Besançon cedex, France; Inserm, UMR1098, 25020 Besançon cedex, France; Université de Franche-Comté, UMR1098, SFR IBCT, 25020 Besançon, France.
³ CHU de Besançon, oncologie, boulevard Fleming, 25030 Besançon cedex, France.
⁴ CHU de Besançon, oncologie, boulevard Fleming, 25030 Besançon cedex, France; Inserm, UMR1098, 25020 Besançon cedex, France; Université de Franche-Comté, UMR1098, SFR IBCT, 25020 Besançon, France. Electronic address: [email protected].

PMID: 30336932
DOI: 10.1016/j.bulcan.2018.08.009

No abstract available

Keywords: Angiogenesis; Angiogenèse; Cancer du rein; Chirurgie; Immunotherapy; Immunothérapie; Renal carcinoma; Sequence; Surgery; Séquence; Targeted therapies; Thérapies ciblées.

Publication types

Editorial

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Antineoplastic Agents / therapeutic use
Cytoreduction Surgical Procedures / methods*
Humans
Kidney Neoplasms / drug therapy
Kidney Neoplasms / surgery*
Nephrectomy / methods*
Prognosis
Randomized Controlled Trials as Topic
Sunitinib / therapeutic use
Treatment Outcome

Substances

Angiogenesis Inhibitors
Antineoplastic Agents
Sunitinib